Bayer says eye drug meets goal in diabetic macular edema trials
FRANKFURT Aug 6 (Reuters) - Bayer said on Tuesday that two late-stage studies testing its drug VEGF Trap-Eye against diabetic macular edema (DME) met their primary goals.
Bayer co-develops the eye drug, also known as Eylea, with Regeneron.
Bayer said that Regeneron now expects to submit an application for U.S. marketing approval for the treatment of DME in 2013, about a year earlier that previously planned.
- Tweet this
- Share this
- Digg this
- Exclusive - Apple, Google agree to pay over $300 million to settle conspiracy lawsuit
- Brazilian Congress passes Internet bill of rights
- Moyes left all at sea by scale of United job, says former coach
- Boy and girl on Korean ferry drowned with life jackets tied together |
- Ukraine forces kill up to five rebels; Russia starts drill near border |